FDA Approves Semaglutide for MASH With Fibrosis
Approval was based on part 1 of the ESSENCE trial, with part 2 results expected in 2029.
Previous Post
Comfort, Targeted Nursing Boost Recovery in Colorectal Surgery
Next Post
STAT+: The best paid CEOs in health care
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago